TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases. The company's lead product candidate is the Cx601, which completed Phase III clinical trials for the treatment of complex perianal fistulas in patients suffering from Crohn's disease. It also engages in developing Cx611, a clinical stage product candidate from its expanded adipose-derived stem cell-based (eASC-based) technology platform, which completed a Phase I study in sepsis and a Phase Ib/IIa trial for the treatment of refractory rheumatoid arthritis; and Cx621, which has completed a Phase I trial for the treatment of intra lymphatic administration of allogeneic eASCs. It is also developing AlloCSC-01, a product candidate based on the CSC-based platform, which has completed a Phase I/II study in acute myocardial infarction. The company has operations in Belgium, Spain, and the United States. TiGenix NV was founded in 2000 and is headquartered in Leuven, Belgium. As of July 3, 2018, TiGenix NV operates as a subsidiary of Takeda Pharmaceutical Company Limited.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TIG
Previous SymbolNYSE:TIG
CUSIPN/A
Phone321-639-6060
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees80
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable
TIGENIX/S (NASDAQ:TIG) Frequently Asked Questions
What is TIGENIX/S's stock symbol?
TIGENIX/S trades on the NASDAQ under the ticker symbol "TIG."
What price target have analysts set for TIG?
2 brokers have issued 1-year target prices for TIGENIX/S's stock. Their forecasts range from $42.80 to $42.80. On average, they anticipate TIGENIX/S's stock price to reach $42.80 in the next twelve months. This suggests a possible upside of 2.0% from the stock's current price. View Analyst Price Targets for TIGENIX/S.
What is the consensus analysts' recommendation for TIGENIX/S?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TIGENIX/S in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for TIGENIX/S.
Has TIGENIX/S been receiving favorable news coverage?
Media coverage about TIG stock has been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. TIGENIX/S earned a coverage optimism score of 1.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are some of TIGENIX/S's key competitors?
Some companies that are related to TIGENIX/S include Advanced Accelerator Application (AAAP), Aerpio Pharmaceuticals (ARPO), AgeX Therapeutics (AGE), American Oriental Bioengineering (AOBI), Anthera Pharmaceuticals (ANTH), Aralez Pharmaceuticals (ARLZ), Argos Therapeutics (ARGS), ARMO Biosciences (ARMO), Biostar Pharmaceuticals (BSPM), Bohai Pharmaceuticals Group (BOPH), Cardiome Pharma (CRME), Concordia International (CXRXD), Concordia International (CXRX), Depomed (DEPO) and Diffusion Pharmaceuticals (DFFN).
Who are TIGENIX/S's key executives?
TIGENIX/S's management team includes the folowing people:
- Dr. Claudia D'Augusta, Chief Financial Officer and Compliance Officer (Age 48)
- Mr. Wilfried Dalemans, Chief Technical Officer (Age 60)
- Claudia Jiménez, Sr. Director of Investor Relations & Communications
- An Moonen, Gen. Counsel and Company Sec.
- Dr. Marie Paule Richard, Chief Medical Officer (Age 63)
When did TIGENIX/S IPO?
(TIG) raised $26 million in an initial public offering on Thursday, December 15th 2016. The company issued 2,800,000 shares at a price of $9.12 per share. BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Canaccord Genuity was co-manager.
How do I buy shares of TIGENIX/S?
Shares of TIG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TIGENIX/S's stock price today?
One share of TIG stock can currently be purchased for approximately $41.98.
What is TIGENIX/S's official website?
How can I contact TIGENIX/S?
TIGENIX/S's mailing address is ROMEINSE STRAAT 12 BOX 2 3001, LEUVEN C9, 3001. The company can be reached via phone at 321-639-6060 or via email at [email protected]
MarketBeat Community Rating for TIGENIX/S (NASDAQ TIG)
MarketBeat's community ratings are surveys of what our community members think about TIGENIX/S and other stocks. Vote "Outperform" if you believe TIG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TIG will underperform the S&P 500 over the long term. You may vote once every thirty days.
